Treatment of respiratory syncytial virus with palivizumab: a systematic review

@article{Hu2010TreatmentOR,
  title={Treatment of respiratory syncytial virus with palivizumab: a systematic review},
  author={Jia Hu and Joan L. Robinson},
  journal={World Journal of Pediatrics},
  year={2010},
  volume={6},
  pages={296-300}
}
BackgroundPalivizumab has proven efficacy for prophylaxis of respiratory syncytial virus (RSV) in infants with prematurity or congenital heart disease. Despite a paucity of data, palivizumab is sometimes used to prevent progression when high-risk patients present with upper respiratory tract infection (URTI) due to RSV, or as therapy when any patients present with severe lower respiratory tract infection (LRTI) caused by RSV.MethodsA systematic review of the literatures on the use of… Expand
Respiratory syncytial virus and palivizumab: Where are we in 2014?
  • Joan L. Robinson
  • Medicine
  • The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale
  • 2014
TLDR
Indications for palivizumab remain controversial because the drug is costly (the drug cost in Canada is approximately $7,500 for five doses for a child with a mean weight of 5 kg), and Wastage is common because vials are preservative free. Expand
A review of palivizumab and emerging therapies for respiratory syncytial virus
TLDR
The modified recommendations for the use of palivizumab espoused by the American Academy of Pediatrics and research on the cost-effectiveness of this product are presented and the historical and current efforts to develop a vaccine targeting RSV are explored. Expand
Respiratory syncytial virus: current and emerging treatment options
TLDR
There is a clear need for novel RSV preventative and therapeutic strategies that may help prevent or decrease the severity of RSV infections in infants and children. Expand
Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections
TLDR
A systematic review of primary population-based studies that examine the incidence of palivizumab breakthrough infections in children, published between 1997 to present and a meta-analysis using pooled effectiveness data are conducted. Expand
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
TLDR
The primary outcomes of mortality, length of hospital stay, and adverse events were assessed as providing low- or very low-certainty evidence due to risk of bias and imprecision and there was no evidence of a significant difference between immunoglobulins and placebo for any of the authors' secondary outcomes. Expand
Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial
TLDR
Intravenous palivizumab did not appear to help or harm young infants with acute RSV-positive bronchiolitis. Expand
Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
TLDR
The prophylaxis of RSV infection in CHD patients is cost-effective in both the medical aspect of the patients as well as the socio-economic aspect and an effort to promote prevention should be made by not only the family of the Patients but also by the government. Expand
Social, economic, and health impact of the respiratory syncytial virus: a systematic search
TLDR
There is a need for interventions aimed at reducing the impact of RSV infection by targeting health education, information, and prophylaxis in high-risk populations and further research is needed on mid- and long-term impact ofRSV infection on the adult population. Expand
Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome
TLDR
This review explores both known risk factors that can lead to severe RSV-induced disease as well as emerging topics in the development of immunity to RSV and the long-term consequences of severe infection. Expand
The Impact of RSV-Associated Respiratory Disease on Children in Asia
TLDR
Empirical studies including surveillance is the key to track the disease burden including risk factors, seasonality, morbidity, and mortality associated with RSV infection in developing countries, and to improve the clinical diagnosis and plan preventive strategies in resource-limited developing countries. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 23 REFERENCES
Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
  • Medicine
  • Pediatrics
  • 1998
Objective. To determine the safety and efficacy of prophylaxis with palivizumab in reducing the incidence of hospitalization because of respiratory syncytial virus (RSV) infection in high-riskExpand
Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection
TLDR
Intravenous palivizumab was safe and well-tolerated in children hospitalized with RSV disease and achieved serum palivIZumab concentrations above the 25- to 30-μg/mL concentration associated with 2-log reduction of pulmonary RSV titer in the cotton rat model. Expand
Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients
TLDR
Treatment of RSV-infected high-risk children with intravenous palivizumab alone or in combination with ribavirin was well tolerated and associated with decreased mortality compared with previous reports. Expand
Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
TLDR
Intravenous palivizumab (15 mg/kg) appears to be safe and well tolerated in HSCT recipients. Expand
Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.
TLDR
RSVIG infusions seemed safe and generally well tolerated and although some beneficial effect trends were seen for those with more severe disease who were treated there was no evidence that treatment with RSVIG resulted in reduced hospitalization and reduced ICU stays in all children with RSv disease. Expand
Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
TLDR
Recommendations for immunoprophylaxis have been updated in an effort to ensure optimal balance of benefit and cost from this expensive intervention and are consistent with the 2009 Red Book recommendations. Expand
Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis
TLDR
Comparing the results of economic analyses of the two agents suggests palivizumab may be the more cost-effective option in the population for which RSV prophylaxis is recommended, and major variation exists in the modelling used in these analyses. Expand
Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections
TLDR
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI. Expand
Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
TLDR
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI. Expand
Impact of respiratory syncytial virus in the United States.
  • R. F. Robinson
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2008
TLDR
RSV infection is associated with significant disease burden in infants and young children in terms of hospitalization, related complications, and even mortality, with significantly higher costs seen in children with risk factors for severe disease and RSV-related complications. Expand
...
1
2
3
...